Electromedical Technologies Announces Financial and Operational Highlights for the Three Months Ended March 31, 2022

 

SCOTTSDALE, AZ -- May 24, 2022 -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three months ended March 31, 2022.

"We continue to drive strong growth on the topline, which is critical given the inherent scalability of our model and our capacity to expand with strong margins," noted Matthew Wolfson, Founder and CEO of Electromedical. "Our flagship device, the WellnessPro plus, has helped thousands upon thousands of people over the past 15 years get their lives back and enjoy a pain free life without the use of opioids. These trends are picking up in our core business and our focus on investing in marketing and sales personnel and initiatives continues to pay off and provide a strong outlook ahead as we move closer toward the commercial launch of our next generation product line."


Financial Performance Highlights for the Three Months Ended Mar 31, 2022

  • Net Sales increased 33% year over year to $221,894
  • Gross Profit increased 24% year over year
  • Gross Margin decreased from 75% to 70%, impacted by additional freight costs to expedite inventory delivery
  • Overall Net Loss dropped 55% year over year to $1.1 million


Operational Highlights for the Three Months Ended Mar 31, 2022

  • Continued investments in Marketing and Sales initiatives.
  • Hired Director of Business and Sales Development with deep industry track record and experience.
  • Made strong R&D gains in development of new product line targeting October 2022 full commercial launch.


Management sees the Company's continued strides in topline growth as further reinforcement for its strategic decision to invest heavily in sales and marketing, both in terms of personnel and other key strategies. In particular, the Company's decision to hire a top industry veteran with a long track record of success, David Orn, as its new Director of Business and Sales Development has been important in driving further topline expansion.

Orn added, "My goal for this year is to onboard  100 active independent medical sales reps, selling the Wellness Pro plus every month."

Wolfson added, "Q1 was a strong start to an exciting year with bold steps ahead. I'm proud of our team and grateful for the new talent we have been adding as we scale our operations, and I look forward to sharing more with our stakeholders as we push past new milestones in the months ahead."

 

About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. 

For more information, please visit www.electromedtech.com.

Note: Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and are currently not cleared in the US.

 

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

 

Corporate Contact:
Electromedical Technologies, Inc.
Tel: 1.888.880.7888
Email: ir@electromedtech.com
https://electromedtech.com

ELECTROMEDICAL TECHNOLOGIES, INC.

BALANCE SHEETS

(UNAUDITED)

 

 

 

 

 

 

 

 

 

    

March 31, 2022

    

December 31, 2021

ASSETS

 

 

  

 

 

  

Current assets:

 

 

  

 

 

  

Cash and cash equivalents

 

$

 170,048

 

$

 383,170

Accounts receivable

 

 

 31,790

 

 

 35,085

Inventories

 

 

 196,924

 

 

 218,510

Prepaid expenses and other current assets

 

 

 24,930

 

 

 38,002

Total current assets

 

 

 423,692

 

 

 674,767

 

 

 

 

 

 

 

Property and equipment, net

 

 

 721,875

 

 

 727,344

Total assets

 

$

 1,145,567

 

$

 1,402,111

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

  

 

 

  

 

 

 

 

 

 

 

Current liabilities:

 

 

  

 

 

  

Accounts payable

 

$

 274,251

 

$

 214,785

Credit cards payable

 

 

 14,686

 

 

 11,283

Accrued expenses and other current liabilities

 

 

 539,237

 

 

 317,037

Customer deposits

 

 

 21,850

 

 

 

Convertible promissory notes, net of discount of $492,877 and $723,166, respectively

 

 

 1,289,476

 

 

 811,687

Related party notes payable

 

 

 

 

 

 57,875

Long term debt, current portion

 

 

 30,490

 

 

 29,502

Total current liabilities

 

 

 2,169,990

 

 

 1,442,169

 

 

 

 

 

 

 

Long-term liabilities:

 

 

  

 

 

  

Bank debt, net of current portion

 

 

 511,613

 

 

 518,849

Government debt, net of current portion

 

 

 153,789

 

 

 154,429

Other liabilities

 

 

 9,204

 

 

 9,167

Total liabilities

 

 

 2,844,596

 

 

 2,124,614

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' deficit

 

 

  

 

 

  

Series A Preferred Stock, $.00001 par value, 1,000,000 shares authorized and 500,000 outstanding

 

 

 355,000

 

 

 355,000

Series B Preferred Stock, $.00001 par value, 1 share authorized and 0 outstanding

 

 

 

 

 

 

Common stock, $.00001 par value, 500,000,000 and 250,000,000 shares authorized; 104,955,567 and 87,725,842 shares outstanding at March 31, 2022 and December 31, 2021, respectively

 

 

 1,048

 

 

 876

Additional paid-in-capital

 

 

 20,401,493

 

 

 20,804,333

Accumulated deficit

 

 

 (22,456,570)

 

 

 (21,882,712)

Total stockholders' deficit

 

 

 (1,699,029)

 

 

 (722,503)

Total liabilities and stockholders' deficit

 

$

 1,145,567

 

$

 1,402,111

 

ELECTROMEDICAL TECHNOLOGIES, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31,

(UNAUDITED)

 

 

 

 

 

 

 

 

 

    

2022

    

2021

Net sales

 

$

 221,894

 

$

 166,440

 

 

 

 

 

 

 

Cost of sales

 

 

 67,641

 

 

 41,951

 

 

 

 

 

 

 

Gross profit

 

 

 154,253

 

 

 124,849

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

 879,810

 

 

 1,689,383

 

 

 

 

 

 

 

Loss from operations

 

 

 (725,557)

 

 

 (1,564,534)

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

Interest expense

 

 

 (213,379)

 

 

 (1,060,302)

Change in fair market value of derivative liabilities

 

 

 

 

 

 14,798

Other income (expense)

 

 

 

 

 

 (428)

Loss on extinguishment of debt

 

 

 (205,600)

 

 

 

Forgiveness of debt

 

 

 

 

 

 50,082

Total other expense

 

 

 (418,979)

 

 

 (995,850)

 

 

 

 

 

 

 

Net loss

 

$

 (1,144,536)

 

$

 (2,560,384)

Deemed dividend related to warrant resets

 

 

 (63,381)

 

 

 (510,222)

Net loss attributable to common stockholders

 

 

 (1,207,917)

 

 

 (3,070,606)

 

 

 

 

 

 

 

Weighted average shares outstanding - basic and diluted

 

 

 97,260,915

 

 

 28,558,027

Weighted average loss per share - basic and diluted

 

$

 (0.01)

 

$

 (0.11)

 

ELECTROMEDICAL TECHNOLOGIES, INC.

STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31,

(UNAUDITED)

 

 

 

 

 

 

 

 

 

    

2022

    

2021

Cash flows from operating activities:

 

 

  

 

 

  

Net loss

 

$

 (1,144,536)

 

$

 (2,560,384)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

  

 

 

  

Stock-based compensation expense

 

 

 361,603

 

 

 1,298,727

Depreciation and amortization

 

 

 5,469

 

 

 5,469

Forgiveness of debt

 

 

 

 

 

 (49,783)

Loss on extinguishment of debt

 

 

 205,600

 

 

 

Amortization of debt discount and day one derivative loss and warrant expense

 

 

 164,710

 

 

 1,010,601

Change in fair value of derivative liabilities- convertible promissory notes

 

 

 

 

 

 (14,798)

Change in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

 3,295

 

 

 (4,178)

Inventories

 

 

 21,586

 

 

 (129,791)

Prepaid expenses and other current assets

 

 

 13,072

 

 

 161,990

Other assets

 

 

 

 

 

 7,000

Accounts payable

 

 

 59,466

 

 

 (42,284)

Credit cards payable

 

 

 3,403

 

 

 (1,057)

Accrued expenses and other current liabilities

 

 

 (33,400)

 

 

 9,817

Customer deposits

 

 

 21,850

 

 

 (18,301)

Other liabilities

 

 

 37

 

 

 (265)

Net cash used in operating activities

 

 

 (317,845)

 

 

 (327,237)

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

Repayments on bank debt

 

 

 (6,888)

 

 

 (6,556)

Related party notes payable-net

 

 

 (57,875)

 

 

 (50,000)

Issuance of convertible promissory notes

 

 

 494,220

 

 

 712,500

Repayments on convertible promissory notes

 

 

 (367,500)

 

 

 

Repayments on notes payable

 

 

 

 

 

 (12,846)

Issuance of common stock for cash - net

 

 

 42,766

 

 

 

Net cash provided by financing activities

 

 

 104,723

 

 

 643,098

 

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

 

 

 (213,122)

 

 

 315,861

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

 

 383,170

 

 

 264,913

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

 170,048

 

$

 580,774

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

Interest

 

$

 72,308

 

$

 16,356

Income taxes

 

$

 

 

$

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

  

 

 

  

 

 

 

 

 

 

 

January 1,2022 adoption of ASU2020-06

 

$

 379,355

 

$

 

Warrants, common stock and beneficial conversion feature issued in conjunction with convertible promissory notes

 

$

 192,996

 

$

 420,096

Derivative liabilities issued in conjunction with convertible promissory notes

 

$

 

 

$

 974,931

Conversion of convertible promissory notes, derivative liabilities and accrued interest into shares of common stock

 

$

 

 

$

 380,103

 

ElectroMedical Technolog... (QB) (USOTC:EMED)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more ElectroMedical Technolog... (QB) Charts.
ElectroMedical Technolog... (QB) (USOTC:EMED)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more ElectroMedical Technolog... (QB) Charts.